Four deals priced this past week, only two of which met the criteria to be included in our 2022 IPO stats. Biotech MAIA Biotechnology (MAIA) offered more shares and priced at the low end to raise $10 million at a $68 million market cap....read more
MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, raised $10 million by offering 2 million shares at $5, the low end of the range of $5 to $7. The company offered 0.3 million more shares than anticipated. The company's lead...read more
US IPO Weekly Recap: Small deals continue to dominate the summer IPO calendar
Four deals priced this past week, only two of which met the criteria to be included in our 2022 IPO stats. Biotech MAIA Biotechnology (MAIA) offered more shares and priced at the low end to raise $10 million at a $68 million market cap....read more
Renaissance Capital’s July IPO Market Update
Seven IPOs raised a combined $228 million in the slowest July in what’s shaping up to be ...read more
Cancer biotech MAIA Biotechnology prices IPO at $5 low end
MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, raised $10 million by offering 2 million shares at $5, the low end of the range of $5 to $7. The company offered 0.3 million more shares than anticipated. The company's lead...read more
US IPO Week Ahead: 2 small IPOs bring esports and cancer immunotherapies to market
Two small deals are scheduled to price in the week ahead as the IPO market stays on track to post ...read more